ALPHAHELIX MOL.DIAGN. SK1 (4MB) - Total Assets
Based on the latest financial reports, ALPHAHELIX MOL.DIAGN. SK1 (4MB) holds total assets worth €13.12 Million EUR (≈ $15.34 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ALPHAHELIX MOL.DIAGN. SK1 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
ALPHAHELIX MOL.DIAGN. SK1 - Total Assets Trend (2022–2025)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's total assets have evolved over time, based on quarterly financial data. See ALPHAHELIX MOL.DIAGN. SK1 shareholders equity for net asset value and shareholders' equity analysis.
ALPHAHELIX MOL.DIAGN. SK1 - Asset Composition Analysis
Current Asset Composition (December 2025)
ALPHAHELIX MOL.DIAGN. SK1's total assets of €13.12 Million consist of 90.9% current assets and 9.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.7% |
| Accounts Receivable | €5.53 Million | 39.4% |
| Inventory | €3.86 Million | 27.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4MB market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALPHAHELIX MOL.DIAGN. SK1's current assets represent 90.9% of total assets in 2025, an increase from 69.7% in 2022.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 27.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 25.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 39.4% of total assets.
ALPHAHELIX MOL.DIAGN. SK1 Competitors by Total Assets
Key competitors of ALPHAHELIX MOL.DIAGN. SK1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ICON Public Limited Company
F:IJF
|
Germany | €16.51 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Cytogen Inc
KQ:217330
|
Korea | ₩62.24 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
ALPHAHELIX MOL.DIAGN. SK1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 1.05 | 1.20 |
| Quick Ratio | 0.68 | 0.70 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €133.00K | €517.00K | €1.86 Million |
ALPHAHELIX MOL.DIAGN. SK1 - Advanced Valuation Insights
This section examines the relationship between ALPHAHELIX MOL.DIAGN. SK1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.66 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | €14.05 Million |
| Market Capitalization | $1.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values ALPHAHELIX MOL.DIAGN. SK1's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ALPHAHELIX MOL.DIAGN. SK1's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ALPHAHELIX MOL.DIAGN. SK1 (2022–2025)
The table below shows the annual total assets of ALPHAHELIX MOL.DIAGN. SK1 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.05 Million ≈ $16.43 Million |
-8.60% |
| 2024-12-31 | €15.37 Million ≈ $17.97 Million |
-19.49% |
| 2023-12-31 | €19.09 Million ≈ $22.32 Million |
-33.71% |
| 2022-12-31 | €28.80 Million ≈ $33.67 Million |
-- |
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to … Read more